

Study of Lipid Profile in Chronic Kidney Disease in Pre-dialysis Patients

Sagar Nanaso Salunkhe

Professor, Department of Biochemistry, Symbiosis Medical College for Women
Gram -lavale, Pune Maharashtra-412115.

How to cite this article: Sagar Nanaso Salunkhe. Study of Lipid Profile in Chronic Kidney Disease in Pre-dialysis Patients. Indian Journal of Public Health Research & Development 2023;14(4).

Abstract

Background: Chronic Kidney Disease (CKD) causes irreversible damage to renal tissue resulting in decreased kidney function. It will affect the cardio-vascular system and leads to morbidity and mortality. Study of lipid profile in chronic kidney disease in pre-dialysis patients

Method: 150 CKD adult patients were studied and compared with 150 controlled group. Lipid profile was studied after a minimum 12 hour fasting. About 10 ml blood was collected from median cubital vein and centrifuged at 5000 rpm for ten minutes then lipid profile was done by VITROS slidemethod. The obtained results in both groups were noted and compared.

Result: Biochemical parameters had significant p values ($p < 0.001$) except serum sodium. Overall dyslipidemia was present in 27 (18%) CKD and absent in 123 (82%) CKD patients out 150, 9 (6%) patients were in 3rd stage, 45 (30%) were at stage-IV, 96 (64%) were at Vth stage. In correlation of lipid profile with GFR, TG, HDL and VLDL had significant p value ($p < 0.001$).

Conclusion: Present pragmatic study proved that, dyslipidemia progress with CKD. Early monitoring of lipid profile may help to control the progression of CKD and avoid morbidity and mortality of CKD patients.

Keywords: Dyslipidemia, cardiovascular, disease, chronic kidney disease, Viro slide method.

Introduction

Chronic kidney disease (CKD) is associated with premature atherosclerosis and increased incidence of cardio vascular morbidity and mortality⁽¹⁾. Several factors contribute to atherogenesis and cardio vascular disease in patients with CKD. The main risk factors are lipid disorders oxidative stress inflammation, physical inactivity, anaemia, hypertension, vascular calcification, endothelial dysfunction and depressed nitric oxide availability⁽²⁾.

Numerous studies have been conducted to compare the features and mechanism of CKD

- induced dyslipidemia. In the plasma, lipid are carried by water soluble particles known as lipoproteins, which consists of nonpolar lipid core (triglycerides, cholesterol esters) surrounded by an envelope composed of specific apolipoproteins (apo) phospholipids and other polar lipids. The plasma lipoproteins are commonly classified as either high density (HDL), low density (LDL), intermediate or very low density (VLDL), lipoproteins according to their ultra-centrifugation characteristics. Chylomicrons and VLDL serve as vehicles to transport triglycerides and cholesterol from the sites of absorption from intestine, liver. In contrast HDL serves as a vehicle to

Corresponding Author: Sagar Nanaso Salunkhe, Professor, Department of Biochemistry, Symbiosis Medical College for Women Gram -lavale, Pune Maharashtra-412115. Formerly, Associate Professor, Department of Biochemistry, Bharati Vidyapeeth, (Deemed to be University) Medical College Pune, Maharashtra 411043.

E-mail: ss061971@gmail.com

transport excess cholesterol from peripheral tissues to the liver for disposal. Hence attempt is made to evaluate the lipid profile to know the severity of CKD.

Material and Method

150 adult patients admitted at tertiary care hospital, Pune-411043 Maharashtra were studied.

Inclusive Criteria: The patients confirmed having CKD (chronic kidney disease) and above the age of 18 years.

Exclusion Criteria: Patients of HIV, hepatitis, terminal stage of cancer patient, below 18 years patients and stage of renal disease (CKD-stage V) on haemodialysis patients having Diabetes mellitus patients already on lipid lowering drug therapy.

Methods: 150 chronic kidney disease patients were compared with 150 normal healthy volunteers (controlled group). Blood samples were drawn cubital fossa after a maximum of 12 hour fasting. About 10ml of blood was drawn and transfused to dried glass plain vials serum was separated within 2 hours after collection and centrifuged at 5000 rpm for 10 minutes. The supernatant clear serum was then pipetted out and stored in dry thin walled vials at 40°C. The samples were analysed on the same day. Study of lipid profile was done by VITROS slide method.

The duration of study was January-2019 to January-2023.

Statistical analysis: Various parameters were compared in Chronic Kidney Disease and controlled group (normal group) with t test and GFR was correlated with Pearson co-efficient regression method. The statistical analysis was carried out in SPSS method. The ratio of male and female was 2:1.

Observation and Results

Table-1: Comparison of Biochemical parameters in CKD patients and controlled groups

- Blood Urea - 206.73 (\pm 82.10) in CKD group, 14.10 (\pm 4.30) in controlled group, t test 28.06 and $p < 0.001$
- S. creatinine - 8.60 (\pm 4.30) in CKD group, 0.75 (\pm 0.23) in controlled group, t test 22.2 and $p < 0.001$

- S. total protein - 6.06 (\pm 0.60) in CKD group, 6.82 (\pm 0.44) in controlled group, t test 11.42 and $p < 0.001$
- S. Albumin - 3.36 (\pm 0.52) in CKD group, 4.22 (\pm 0.32) in controlled group, t test 10.1 and $p < 0.001$
- S. Sodium - 139.60 (\pm 6.11) in CKD group, 140.45 (\pm 5.18) in controlled group, t test 1.18 and $p < 0.23$ (p value is insignificant)
- S. Potassium - 5.62 (\pm 2.10) in CKD group, 14.10 (\pm 4.30) in controlled group, t test 28.06 and $p < 0.001$
- S. Calcium - 8.38 (\pm 1.26) in CKD group, 8.95 (\pm 0.75) in controlled group, t test 4.47 and $p < 0.001$
- S. Phosphorous - 7.32 (\pm 2.14) in CKD group, 3.65 (\pm 0.82) in controlled group, t test 19.01 and $p < 0.001$
- Haemoglobin - 7.60 (\pm 1.50) in CKD group, 12.05 (\pm 1.60) in controlled group, t test 22.08 and $p < 0.001$

Note: (sr. sodium) all parameters have significant p value ($p < 0.001$)

Table-2: Prevalence of individual and overall study of Dyslipidemia in both CKD and controlled group.

Lipid profile parameter

- TC - CKD < 260 - 76 (50.6%), 74 in controlled, CDD > 200 74 (49.3%), 26 in controlled group
- TG < 150 - 48 (32%) in CKD, 68 in controlled group, > 150 102 (68%) in CKD, 32 in controlled group
- HDL < 40 - 110 (73%) in CKD group, 22 in controlled group, 40-60 40 (26.6%) in CKD group, 78 in controlled group
- LDL < 130 - 87 (58%) in CKD group, 69 in controlled group, > 130 - 63 (42%) in CKD group, 31 in controlled group
- VLDL < 30 - 48 (32%) in CKD group, 89 in controlled group, > 30 102 (68%) in CKD group, 11 in controlled group

Overall N (present) 27 (18%) in CKD Dyslipidemia, 6 in controlled group, absent in 123 (82%) in CKD and 45 in controlled group.

Table-3: Study of profile in CKD patients at various stage

Stage-I - NIL, Stage-II - NIL

Stage-III - Number of patients 9 194.6 (± 55.6) TG, 40.30 (± 5.40) HDL, 115.2 (±17.4) LDL, 26.4 (±10.62) VLDL

Stage-IV - Number of patients 45 - 198.4 (± 42.2) TC, 152.4 (±66.4)TG, 39.16 (± 6.80) HDL, 119 (±36.12) LDL, 32.46 (± 14.8) VLDL

Stage-V - 96 patients - 208 v42.15) TC, 192.8 (± 56.68) TG, 35.63 (± 4.82) HDL, 126.8 (±36.29) LDL, 39.22 (± 12.15) VLDL

Table-4: Correlation of lipid profile parameters with GFR

0.100 TC, 0.306 TG, 0.325 HDL, 0.108 LDL, 0.275 VLDL

P value was significant in TG, HDL and VLDL

Mean GFR 1175 (± 7.93) ml/min/1.73 m²

Table 1: Comparison of Biochemical parameters in CKD patients and controlled group

No. of CKD patients: 150

Sl. No	Biochemical parameters	CKD group 150	Controlled group 100	t test	p value
1	Blood Urea	206.73 (± 82.10)	14.10 (± 4.30)	28.6	P<0.001
2	Serum creatinine	8.60 (± 4.30)	0.75 (± 0.28)	22.2	P<0.001
3	Serum total protein	6.06 (± 0.60)	6.82 (± 0.44)	11.42	P<0.001
4	Serum Albumin	3.36 (± 0.52)	4.22 (± 0.32)	16.1	P<0.001
5	Serum sodium	139.60 (± 6.11)	140.45 (± 5.18)	1.18	p>0.23
6	Serum potassium	5.62 (± 1.28)	4.26 (± 0.70)	10.8	P<0.001
7	Serum Calcium	8.38 (± 1.26)	8.95 (± 0.75)	4.47	P<0.001
8	Serum phosphorous	7.32 (± 2.14)	3.65 (± 0.82)	19.01	P<0.001
9	Haemoglobin	7.60 (± 1.50)	12.05 (± 1.60)	22.08	P<0.001

Except serum sodium all value have significant p value (p<0.001)

Table 2: Prevalence of Individual and overall study of Dyslipidemia in both controlled and CKD group

Lipid profile parameter	CKD group with % 150			Controlled group with 100%
	<200	76	506	
TC	<200	76	506	74
	>200	74	49.3	26
TG	<150	48	32	68
	>150	102	68	32
HDL	<40	110	73	22
	40-60	40	266	78
LDL	<130	87	58	69
	>130	63	42	31
VLDL	<30	48	32	89
	>30	102	68	11
Overall prevalence	N	27	18	55
	Ab	123	82	45

Table 3: Study of lipid profile in CKD patients at various stages

CKD stage	No. of cases	TC	TG	HDL	LDL	VLDL
1	0	--	--	--	--	--
2	0	--	--	--	--	--
3	9 (6%)	194.6 (±22.20)	146.2 (±55.60)	40.30 (±5.40)	115.2 (±17.48)	26.40 (±10.62)
4	45 (30%)	198.4 (±42.25)	152.4 (±66.49)	39.16 (±6.80)	119.6 (±36.12)	32.46 (±14.80)
5	96(±64%)	208 (±42.15)	192.8 (±56.68)	35.63 (±4.82)	126.8 (±36.29)	39.22 (±12.15)

Table 4: Correlation of lipid profile parameter with GFR

		GFR	TC	TG	HDK	LDL	VLDL
GFR	Pearson correlation	1	0.100	0.306	0.325	0.108	0.275
	P value		0.26	0.001	0.001	0.242	0.002

TG, HDL and VLDL have significant correlation with GFR but TC, LDL have insignificant correlation

Note: Mean GFR = 11.75±7.93 ml/min/1.73 m²

Discussion

Present study of lipid profile in CKD patients of Maharashtra population. In the comparison of biochemical parameters in CKD patients and controlled groups except serum sedum all values were highly significant (p<0.001) (Table-1). Study of prevalence of Individual and overall study of dyslipidemia in both controlled group and CKD patients 27 (18%) had presences dyslipidemia and 23 (82%) had absence of dyslipidemia (Table-2). The study of lipid profile in CKD patients at various stage.

3rd stage had 9 (6%), 4th stage had 45 (30%), Vth stage had 96 (64%) CKD patients with elevated

lipid profile (Table-3). In correlation of lipid profile parameters with GFR - TR, HDL and VLDL have significant correlation with GFR mean GFR = 11.75 (± 7.93) ml/min/1.73 m² (Table-4). These findings are more or less agreement with previous studies⁽⁵⁾⁽⁶⁾⁽⁷⁾.

Hyperlipidemic can potentially accelerate progression of renal disease by several mechanisms. First resorption of fatly acids phospholipids, and cholesterol contained in the filtered proteins (albumin and lipoproteins) by tubular epithelial cells can stimulate tubule-interstitial inflammation, foam cell formation and tissue injury⁽⁸⁾. Second factor is accumulation of lipoproteins in glomerular

mesangium can promote matrix production and glomerulo-sclerosis⁽⁹⁾. In addition to this impaired HDL mediated reverse cholesterol transport can further contribute to tissue injury by limiting the unloading of the excess cellular cholesterol and phospho lipid burden. In fact low plasma HDL had been identified as an independent risk factor for progression of renal disease⁽¹⁰⁾. Moreover of hereditary Lecithin cholesterol acyltransferase (LCAT) deficiency, this is associated with marked reduction in HDL: cholesterol and impaired HDL mediated reverse cholesterol transport results in progressive renal disease (11).

It is reported that, consumption of high fat diet exacerbates hyper lipidemia whereas correction of hyperlipidemia attenuates the severity of glomerulo sclerosis and tubulo intestinal fibrosis in animal studies⁽¹²⁾. Moreover pharmacological intervention aimed at normalization of HDL metabolism per se with no change in serum total cholesterol has been shown to retard the progression of renal disease in 5/6 nephrectomised rats⁽¹⁵⁾. Numerous factors contribute to atherogenic diathesis and high risk of cardio vascular disease in CKD. These include oxidative stress inflammation, hypertension and altered metabolism of lipids carbohydrate Nitric oxide calcium and phosphate in CKD patients.

Summary and Conclusion

Dyslipidemia is a common cardio vascular risk factor CKD in adult patients. Some lipid abnormalities such as reduced HDL elevated TG and atherogenic risk tends to increase with worsening renal function. Statin exert positive effects in CKD and renal transplanted patients, where no advantage have been revealed in end stage renal disease patients in terms of survival or cardio vascular morbidities. New hypolipidemic therapies lead to an additional lowering cholesterol levels but further studies are necessary to evaluate their potential application to CKD patients in order to improve clinical outcomes because exact pathogenesis of dyslipidemia is still un-clear.

Limitation of study: Owing to tertiary location of research centre, small number of patients and lack of latest technologies, we have limited findings and results.

This research paper is approved by Ethical committee of Bharati Vidyapeeth (deemed to be university) medical college pune-411043 (Maharashtra)

Conflict of Interest: No

Funding: Self

References

1. Adler AL, Stevens RJ - Development and progression of nephropathy in type-2 Diabetes the United Kingdom prospective diabetes study kidney Int 2003, 63; 225-232.
2. Dan L, Longo Demis L, Kasper - Harrisons principles of Internal medicine 18th edition New Delhi McGraw Hill 2002, 2; 2308-09.
3. Liu M, Lixc Lu L - Cardio vascular disease and its relation with chronic kidney disease Eur Rev. Med. Pharmacol, Sci. 2014, 18 (18); 2918-20
4. Vishwam pandya Akhilesh Rao kunal choudhary - Lipid abnormalities in kidney disease and management strategies world J. Nephrol 2015, Feb 4(1); 83-91.
5. Gourav Gary Sumitpal Singh- A clinical study of dyslipidemic in patients of chronic kidney disease Ind. J. Bioassay 2015, 4 (3); 3732-3737.
6. Manpreet Saini, Amrita vanme visay kumar - The study of pattern of lipid profile in chronic kidney disease patients on conservative management and Haemodialysis cures 2022, 2-5.
7. Webster AC, Megler SV - Chronic kidney disease Lancet 2016, 389; 1258-52.
8. Brun skill NJ - Albumin signals the coming of age of proteinuria nephropathy J. Am. Soc. Nephrol. 2004, 15; 504-505.
9. Lee HS, Lee JJ - Intraglomerular lipid deposition in routine biopsies clin. Nephrol. 1991, 36; 67-75.
10. Hunisicker LG, Adler S - Predictor of the progression of renal disease in the modification diet in renal disease study kidney Int. 1997, 51; 1908-1919.
11. Kuivenhiven JA, Pritchard H - The molecular pathology of lecithin cholesterol acyltransferase (LCAT) deficiency syndrome J. lipid Res. 1997, 38; 191-205.
12. Kasike BI, O'Donnell NP - The role of lipid abnormalities in the pathogenesis of chronic progressive renal disease Adv. Nephrol Necker Hosp. 1991, 20; 109-125.
13. Vazir ND and Liang K - AC AT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure Am. J. Phy. Sol renal physiol. 2004, 287; 1038-1043.